AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27990769 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of brushing orders
Number of subjects: 46
Study 27016644 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS 8
Number of subjects: 766
Study 27016644 — intervention group
Group type: COMPARATOR
Intervention: ENG implant
Number of subjects: 766
Study 24636948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dietetic support
Number of subjects: 192
Study 24636948 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized knee exercise program
Number of subjects: 192
Study 24636948 — intervention group
Group type: EXPERIMENTAL
Intervention: No attention
Number of subjects: 192
Study 24636948 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet and no attention)
Number of subjects: 192
Study 22971985 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) - cooking activities once a week for 15 weeks
Number of subjects: 38
Study 22971985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cooking activities)
Number of subjects: 38
Study 20462664 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg of ustekinumab
Number of subjects: 1230
Study 20462664 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of ustekinumab
Number of subjects: 1230
Study 20462664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study 18573392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy (5 mU/kg/min) with dextrose 20% to maintain blood glucose levels between 70 and 110 mg/dL (group II)
Number of subjects: 52
Study 18573392 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative intravenous insulin infusion, titrated to maintain blood glucose concentrations less than 180 mg/dL (group I)
Number of subjects: 52
Study 16143197 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost intratympanic injection (once daily for 3 days)
Number of subjects: 0
Study 16143197 — intervention group
Group type: COMPARATOR
Intervention: Placebo intratympanic injection
Number of subjects: 0
Study 11828277 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting
Number of subjects: 144
Study 11828277 — intervention group
Group type: COMPARATOR
Intervention: Conventional harvesting
Number of subjects: 144
Study 10618936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 1 mg
Number of subjects: 86
Study 10618936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 2 mg
Number of subjects: 86
Study 10618936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 4 mg
Number of subjects: 86
Study 10618936 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline (control)
Number of subjects: 86
Study 7582326 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological filter for single sweep records of ERP
Number of subjects: 9
Study 1951152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (low-fat diet instruction)
Number of subjects: 303
Study 1951152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303
Study 6406705 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids alone (1.4 g/kg/day)
Number of subjects: 93
Study 6406705 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (1.4 g/kg/day) plus 5% dextrose
Number of subjects: 93
Study 6406705 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose alone
Number of subjects: 93
Study 31044746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Explained (detailed explanation of the procedure)
Number of subjects: 184
Study 31044746 — intervention group
Group type: COMPARATOR
Intervention: Group Unexplained (brief explanation of the procedure)
Number of subjects: 184
Study 29092028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Mental Component Summary (MCS) score
Number of subjects: 762
Study 29092028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Physical Component Summary (PCS) score
Number of subjects: 762
Study 27102812 — intervention group
Group type: EXPERIMENTAL
Intervention: blended Cognitive Behavioural Therapy (bCBT) combining face-to-face and online sessions over 19-20 weeks
Number of subjects: 0
Study 27102812 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 0
Study 27102812 — intervention group
Group type: EXPERIMENTAL
Intervention: blended Cognitive Behavioural Therapy (bCBT)
Number of subjects: 0
Study 24399768 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerh tea extract capsule (333 mg Puerh tea extract) three times a day
Number of subjects: 70
Study 24399768 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 70
Study 22771129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent/family dyads discussing advance directives
Number of subjects: 48
Study 22771129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent/family dyads' thoughts about dying in pain
Number of subjects: 48
Study 22771129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent/family dyads' thoughts about being off life support machines
Number of subjects: 48
Study 22771129 — intervention group
Group type: EXPERIMENTAL
Intervention: Families' knowledge of teens' preferences for timing of EOL conversations
Number of subjects: 48
Study 22771129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents' desire to discuss EOL issues
Number of subjects: 48
Study 21073130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 48
Study 21073130 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary conventional treatment alone)
Number of subjects: 48
Study 17668232 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU rHuEpo every second day for 14 days, followed by a single dose of 5,000 IU weekly for 10 weeks
Number of subjects: 8
Study 15731394 — intervention group
Group type: EXPERIMENTAL
Intervention: ECW measurement in African Americans
Number of subjects: 1538
Study 15731394 — intervention group
Group type: EXPERIMENTAL
Intervention: ECW measurement in females
Number of subjects: 1538
Study 15731394 — intervention group
Group type: EXPERIMENTAL
Intervention: ECW measurement in males
Number of subjects: 1538
Study 11970778 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with extreme speed ('cheetah')
Number of subjects: 0
Study 11970778 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with extreme slowness ('turtle')
Number of subjects: 0
Study 11970778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived comparability experimentally varied
Number of subjects: 0
Study 9813955 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (fixed dose for at least 1 month)
Number of subjects: 29
Study 8106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live cold-adapted (ca) influenza A vaccine
Number of subjects: 130
Study 8106759 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular trivalent inactivated (triv) influenza vaccine
Number of subjects: 130
Study 8106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 130
Study 2759221 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (8 minute bicycle ride at 90% of predicted heart-rate)
Number of subjects: 86
Study 2759221 — intervention group
Group type: COMPARATOR
Intervention: Control day (no exercise)
Number of subjects: 86
Study 2759221 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 86
Study 1131627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of primidone and phenytoin
Number of subjects: 50
Study 1131627 — intervention group
Group type: COMPARATOR
Intervention: Primidone alone
Number of subjects: 50
Study 31891225 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH-I)
Number of subjects: 89
Study 31891225 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective adherence parameters (number of messages exchanged, days with a completed food diary, days spent per module)
Number of subjects: 89
Study 31891225 — intervention group
Group type: EXPERIMENTAL
Intervention: Not completing the food diary in week 7
Number of subjects: 89
Study 31891225 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' body mass index
Number of subjects: 89
Study 31059418 — intervention group
Group type: COMPARATOR
Intervention: 9 months of twice‐weekly isoniazid (9H)
Number of subjects: 214
Study 31059418 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 once‐weekly doses of isoniazid and rifapentine (3HP)
Number of subjects: 214
Study 28733656 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid and cyclophosphamide (50-100 mg per day)
Number of subjects: 102
Study 28733656 — intervention group
Group type: COMPARATOR
Intervention: Prednisone monotherapy (0.5-1.0 mg/kg.d, tapered gradually)
Number of subjects: 102
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use among men (89.4%) vs. women (55.2%)
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use among men vs. women
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use among men vs. women
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use among men vs. women
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at first consumption of cannabis
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of number of substances used on age at onset of psychosis in women
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of number of substances used on age at onset of psychosis in men
Number of subjects: 114
Study 26513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of age at onset of psychosis
Number of subjects: 114
Study 23032085 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Cl(crea-urea)
Number of subjects: 12
Study 23032085 — intervention group
Group type: EXPERIMENTAL
Intervention: cP-Cl(EDTA)
Number of subjects: 12
Study 23032085 — intervention group
Group type: COMPARATOR
Intervention: U-Cl(EDTA)
Number of subjects: 12
Study 23032085 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(CysC)
Number of subjects: 12
Study 21742284 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil applied to abdominal skin area twice a day until the end of the study term
Number of subjects: 0
Study 21742284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oil used)
Number of subjects: 0
Study 19832737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg
Number of subjects: 70
Study 19832737 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 70
Study 16884439 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI) treatment for 12 weeks
Number of subjects: 55
Study 16884439 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study 15293587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care unit-based nursing screening intervention using the Discharge Planning Questionnaire (n = 47)
Number of subjects: 100
Study 15293587 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge planning (n = 53)
Number of subjects: 100
Study 11402106 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a, 44 microg three times weekly for 3 years
Number of subjects: 618
Study 11402106 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a, 22 microg three times weekly for 3 years
Number of subjects: 618
Study 11402106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interferon beta-1a groups
Number of subjects: 618
Study 11402106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 9230722 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM) 24 micrograms twice daily for 4 weeks
Number of subjects: 12
Study 9230722 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo (PL)
Number of subjects: 12
Study 9230722 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM) + oral prednisolone 50 mg
Number of subjects: 12
Study 9230722 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM)
Number of subjects: 12
Study 9230722 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM) + systemic corticosteroid
Number of subjects: 12
Study 8501271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% delmopinol HCl (aqueous solution)
Number of subjects: 3
Study 8501271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2960701 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 12
Study 2960701 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg loratadine
Number of subjects: 12
Study 2960701 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg loratadine
Number of subjects: 12
Study 2960701 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg descarboethoxyloratadine
Number of subjects: 12
Study 2960701 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg descarboethoxyloratadine
Number of subjects: 12
Study 2960701 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg descarboethoxyloratadine
Number of subjects: 12
Study 30165429 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IGF1R expression
Number of subjects: 769
Study 30165429 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IGF1R expression in ERG-positive tumors
Number of subjects: 769
Study 30165429 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IGF1R expression in ERG-negative tumors
Number of subjects: 769
Study 30165429 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IR expression
Number of subjects: 769
Study 27363307 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dietary feedback system
Number of subjects: 369
Study 27363307 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated dietary feedback system
Number of subjects: 369
Study 25286702 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenlight photoselective vaporization of prostate (PVP)
Number of subjects: 53
Study 25286702 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic resection of prostate (PRP)
Number of subjects: 53
Study 25286702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PVP and PRP
Number of subjects: 53
Study 23072093 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (group A)
Number of subjects: 163
Study 23072093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz electroacupuncture (group B)
Number of subjects: 163
Study 23072093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz electroacupuncture (group C)
Number of subjects: 163
Study 23072093 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (group D)
Number of subjects: 163
Study 23072093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz transcetaneous acupoints electrical stimulation (group E)
Number of subjects: 163
Study 19959537 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low cerebral blood volume (VLCBV) with a cutpoint at 2 mL and <2.5th percentile threshold
Number of subjects: 91
Study 19959537 — intervention group
Group type: COMPARATOR
Intervention: Diffusion-weighted imaging (DWI) lesion volume
Number of subjects: 91
Study 19959537 — intervention group
Group type: COMPARATOR
Intervention: Thresholded apparent diffusion coefficient lesion volume
Number of subjects: 91
Study 18187242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 30
Study 18187242 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant controls
Number of subjects: 30
Study 16192258 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (7 cups/day for 2 weeks)
Number of subjects: 22
Study 16192258 — intervention group
Group type: COMPARATOR
Intervention: Water (7 cups/day for 2 weeks)
Number of subjects: 22
Study 14510091 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose povidone-iodine
Number of subjects: 120
Study 10768517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime + Metronidazole (2 g cefepime + 500 mg metronidazole)
Number of subjects: 615
Study 10768517 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone + Metronidazole (2 g ceftriaxone + 500 mg metronidazole)
Number of subjects: 615
Study 8777468 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 0.004 microgram/kg/min
Number of subjects: 14
Study 8777468 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 0.008 microgram/kg/min
Number of subjects: 14
Study 8777468 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 0.016 microgram/kg/min
Number of subjects: 14
Study 8777468 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (V)
Number of subjects: 14
Study 8777468 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF (all doses)
Number of subjects: 14
Study 1325989 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin-F2 alpha instillation into the solitary tube and systemic prostaglandin administration
Number of subjects: 1
Study 1325989 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment for tubal pregnancy
Number of subjects: 1
Study 6664677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% betaxolol ophthalmic solution
Number of subjects: 24
Study 6664677 — intervention group
Group type: COMPARATOR
Intervention: Placebo drop
Number of subjects: 24
Study 30669763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose group (100 kV + ASIR)
Number of subjects: 100
Study 30669763 — intervention group
Group type: COMPARATOR
Intervention: Normal dose group (120 kV + FPP)
Number of subjects: 100
Study 30669763 — intervention group
Group type: COMPARATOR
Intervention: Normal dose group (120 kV + FBP)
Number of subjects: 100
Study 28376345 — intervention group
Group type: COMPARATOR
Intervention: No variability
Number of subjects: 0
Study 28376345 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative timing variability
Number of subjects: 0
Study 28376345 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute timing variability
Number of subjects: 0
Study 28376345 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in both absolute and relative timing
Number of subjects: 0
Study 26446330 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg bolus, 0.02‐0.1 mg/kg/hr infusion)
Number of subjects: 60
Study 26446330 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg/kg bolus, 1‐3 mg/kg/hr infusion)
Number of subjects: 60
Study 24095618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 200mg
Number of subjects: 18
Study 24095618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19022622 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 24
Study 17542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet A
Number of subjects: 0
Study 17542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet B
Number of subjects: 0
Study 17542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule
Number of subjects: 0
Study 16335333 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian-hops combination (2 nightly tablets for 28 days, n = 59)
Number of subjects: 184
Study 16335333 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (2 tablets of 25 mg for 14 days followed by placebo for 14 days, n = 60)
Number of subjects: 184
Study 16335333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 28 days, n = 65)
Number of subjects: 184
Study 16335333 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian-hops combination (n = 59)
Number of subjects: 184
Study 16335333 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (n = 60)
Number of subjects: 184
Study 12172357 — intervention group
Group type: EXPERIMENTAL
Intervention: IN midazolam (n = 30)
Number of subjects: 81
Study 12172357 — intervention group
Group type: EXPERIMENTAL
Intervention: IV midazolam (n = 28)
Number of subjects: 81
Study 12172357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 81
Study 10446797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 40
Study 7588824 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 38
Study 7588824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7588824 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (no mutation)
Number of subjects: 38
Study 2178660 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 8
Study 2178660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg and 800 mg)
Number of subjects: 8
Study 2178660 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (administered after baseline measurements)
Number of subjects: 8
Study 2178660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for indomethacin)
Number of subjects: 8
Study 92062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% pyrethrins synergized by 3.0% piperonyl butoxide (RiD)
Number of subjects: 30
Study 92062 — intervention group
Group type: COMPARATOR
Intervention: 1% gamma-benzene hexachloride (Kwell)
Number of subjects: 30
Study 31117807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to resist social pressure to use tobacco/betel nut
Number of subjects: 2449
Study 31117807 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cigarette use among middle school students
Number of subjects: 2449
Study 31117807 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokeless tobacco use among middle school students
Number of subjects: 2449
Study 31117807 — intervention group
Group type: EXPERIMENTAL
Intervention: Current e-cigarette use among middle school students
Number of subjects: 2449
Study 31117807 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Pacific Islanders
Number of subjects: 2449
Study 28345790 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl ghrelin infusion (1 pmol kg-1 min-1)
Number of subjects: 18
Study 26444729 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP (150 mg subcutaneously every 4 weeks)
Number of subjects: 1841